Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Modeling Coronavirus – Cytokine Storm

Posted on September 4th, 2020 by

Figure 1. Classification of COVID-19 Disease States.
Adapted from Sidiqi, H.K. and M.R. Mehra, COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant, 2020. [1]

(This piece was co-authored by Prof. Gordon Broderick, Clinical Systems Biology at Rochester General Hospital.)

The thing that kills you with coronavirus is not necessarily the infection itself but rather your own body’s response to the infection. Failure to clear the virus with an appropriate immune response can lead to pulmonary symptoms of increasing severity and which can even be fatal in a minority of cases (Figure 1). This late stage of a COVID-19 infection is characterized by a state of hyperinflammation or, as it is more commonly known, a “cytokine storm”.

(more…)

Research Data Alliance Releases Guidelines for COVID-19 Data Sharing

Posted on July 24th, 2020 by

The Research Data Alliance (RDA) has released its final version of the RDA COVID-19 Recommendations and Guidelines on data sharing for COVID-19, which covers four main research areas: clinical data, omics practices, epidemiology and social sciences. The document also touches on issues like community participation, legal and ethical considerations, research software and indigenous data.

(more…)

5 Ways RWE is Fueling the Fight Against COVID-19

Posted on June 19th, 2020 by

As we discussed in an earlier blog post, real-world evidence can bring value to every stage of the drug life cycle, from early discovery to post-market. Now, as the worldwide research community continues to battle the COVID-19 pandemic, we are also discovering how real-world data and real-world evidence have something to offer in these efforts as well.

(more…)

Drug Repurposing for SARS-CoV-2 Using Network Polypharmacological Approach

Posted on June 9th, 2020 by

Drug development is a multidisciplinary field that requires a drug to successfully pass through different stages — from chemical design to biological experimentation on cells and animals, and finally three phases of human clinical trials — before being approved by the FDA for clinical administration. However, following such a path would not be feasible under circumstances where rapid discoveries are required, such as in the case of the current SARS-CoV-2 outbreak. Hence, repurpose of already approved FDA drugs could help in such circumstances, which can save effort, time and money.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 7